The Impact Of Rituxan For The Treatment Of Follicular Lymphoma.
New probe provides more exhibit that treating certain lymphoma patients with an high-priced drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly inflate life span, raising questions about whether it's worth taking. People with lymphoma who are in maintenance treatment "really need a discussion with their oncologist," said Dr Steven T Rosen, headman of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago cersex colombia. The ponder involved people with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a time that refers to cancers of the immune system.
Though it can be fatal, most nation live for at least 10 years after diagnosis. There has been debate over whether people with the disease should drive Rituxan as maintenance therapy after their initial chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical plc that sells Rituxan, roughly half of the 1019 participants took Rituxan, and the others did not muslim. All in the old days had taken the drug right after receiving chemotherapy.
In the next three years, the go into found, people taking the drug took longer, on average, to come forth symptoms. Three-quarters of them made it to the three-year mark without progression of their illness, compared with about 58 percent of those who didn't require the drug. But the death rate over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.
Showing posts with label rituxan. Show all posts
Showing posts with label rituxan. Show all posts
Friday, 27 July 2018
Friday, 28 February 2014
New Research In The Treatment Of Cancer Of Immune System
New Research In The Treatment Of Cancer Of Immune System.
New analysis provides more exhibit that treating certain lymphoma patients with an priceless drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly further life span, raising questions about whether it's worth taking. People with lymphoma who are light of maintenance treatment "really need a discussion with their oncologist," said Dr Steven T Rosen, cicerone of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago amikacide amp price. The inquiry involved people with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a dub that refers to cancers of the immune system.
Though it can be fatal, most individuals live for at least 10 years after diagnosis. There has been debate over whether people with the disease should take dow a note Rituxan as maintenance therapy after their initial chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical suite that sells Rituxan, roughly half of the 1,019 participants took Rituxan, and the others did not automotive cars. All theretofore had taken the drug right after receiving chemotherapy.
In the next three years, the contemplate found, people taking the drug took longer, on average, to strengthen symptoms. Three-quarters of them made it to the three-year mark without progression of their illness, compared with about 58 percent of those who didn't lay hold of the drug. But the death rate over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.
New analysis provides more exhibit that treating certain lymphoma patients with an priceless drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly further life span, raising questions about whether it's worth taking. People with lymphoma who are light of maintenance treatment "really need a discussion with their oncologist," said Dr Steven T Rosen, cicerone of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago amikacide amp price. The inquiry involved people with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a dub that refers to cancers of the immune system.
Though it can be fatal, most individuals live for at least 10 years after diagnosis. There has been debate over whether people with the disease should take dow a note Rituxan as maintenance therapy after their initial chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical suite that sells Rituxan, roughly half of the 1,019 participants took Rituxan, and the others did not automotive cars. All theretofore had taken the drug right after receiving chemotherapy.
In the next three years, the contemplate found, people taking the drug took longer, on average, to strengthen symptoms. Three-quarters of them made it to the three-year mark without progression of their illness, compared with about 58 percent of those who didn't lay hold of the drug. But the death rate over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.
Subscribe to:
Posts (Atom)